pharmaphorum
LightNews LightNews
banner
pharmaphorum.bsky.social
pharmaphorum
@pharmaphorum.bsky.social
140 followers 480 following 1.2K posts
pharmaphorum.com, and its magazine Deep Dive, is a leading online destination for pharmaceutical industry and healthcare news, insight, and debate
Posts Replies Media Videos
pharmaphorum.bsky.social
Guidance in the #UK has cleared the way for #NHS use of #digitalhealthtechnologies (DHTs) that can support people with #osteoarthritis and the eating disorder #bulimia.
Digital osteoarthritis, bulimia tools backed for NHS use
Guidance in the UK has cleared the way for NHS use of digital health technologies for people with osteoarthritis and eating disorder bulimia.
buff.ly
January 23, 2026 at 4:30 PM
pharmaphorum.bsky.social
#Sanofi has said it will press ahead with #regulatoryfilings for #atopicdermatitis (AD) candidate #amlitelimab after reporting positive data in two more phase 3 trials.
Sanofi plans amlitelimab dermatitis filing after new readout
Sanofi has said it will press ahead with regulatory filings for atopic dermatitis candidate amlitelimab, despite mixed data in phase 3.
buff.ly
January 23, 2026 at 2:30 PM
pharmaphorum.bsky.social
#China's #CorxelPharmaceuticals' latest round is further evidence of #biotech #investors' insatiable appetite for companies with #obesity programmes, with backers ploughing $287 million into its Series D.
Corxel's raises $287m for obesity drug, and other financings
Our latest biofinancing round-up sees big rounds for Corxel and Caldera, with Mendra, Think Bio, Exciva, Cytotheryx, and Infinitopes also raising cash.
buff.ly
January 23, 2026 at 1:00 PM
pharmaphorum.bsky.social
Thousands of men with advanced #prostatecancer will be offered a new treatment, #Pfizer's #Talzenna, from today after #NICE made an about-turn on the drug.

pharmaphorum.com/news/change-...
January 23, 2026 at 11:33 AM
pharmaphorum.bsky.social
After #CorceptTherapeutics setback with #relacorilant in Cushing syndrome last month, the company has bounced back with strong data in #ovariancancer, firming its share price.

pharmaphorum.com/news/ovarian...
Ovarian cancer data restores faith in Corcept's relacorilant
After Corcept's setback with relacorilant in Cushing syndrome last month, the company has bounced back with strong survival data in ovarian cancer.
pharmaphorum.com
January 23, 2026 at 10:23 AM
pharmaphorum.bsky.social
US healthcare giant #JohnsonandJohnson has said that after a "catapult year" in 2025, it is on course to report around $100 billion in #sales this year for the first time.

pharmaphorum.com/news/jj-says...
January 22, 2026 at 2:22 PM
pharmaphorum.bsky.social
#Amazon has become the latest #techcompany to introduce an #AI-powered assistant that is designed to provide #healthguidance based on #medicalrecords.

pharmaphorum.com/news/amazon-...
Amazon joins the AI health assistant movement
Amazon has become the latest tech company to introduce an AI-powered assistant designed to provide health guidance based on medical records.
pharmaphorum.com
January 22, 2026 at 1:20 PM
pharmaphorum.bsky.social
#Roche's #Gazyvaro, a drug that can restore #kidneyfunction in people living with #lupusnephritis, has been cleared for use by the #NHS in England and Wales.

pharmaphorum.com/news/nice-ba...
January 22, 2026 at 12:00 PM
pharmaphorum.bsky.social
A year after President #Trump signed an #executiveorder for the #US to #withdraw from the World Health Organization (#WHO), the exit is formally taking place today, leaving global defences against #healththreats weakened.

pharmaphorum.com/news/us-chec...
US checks out of WHO, leaving its bill unsettled
A year after President Trump signed an order for the US to withdraw from the WHO, the exit is taking place today, with $260m in fees left unpaid.
pharmaphorum.com
January 22, 2026 at 11:24 AM
pharmaphorum.bsky.social
Medicines for #obesity, #diabetes, #rarediseases, #cancer, and #womenshealth feature among #Clarivate's annual round-up of 11 #DrugstoWatch this year, but two of them far outstrip the others in sales potential.

pharmaphorum.com/news/11-high...
11 high-impact drugs to look out for in 2026
Medicines for obesity, diabetes, rare diseases, cancer, and women's health feature among Clarivate's annual round-up of 11 Drugs to Watch this year.
pharmaphorum.com
January 22, 2026 at 10:33 AM
pharmaphorum.bsky.social
The #EuropeanCommission has approved #Otsuka's #Dawnzera for the prevention of recurrent attacks in #raredisease hereditary angioedema (#HAE), a drug that can be self-administered by patients with weeks between doses.

pharmaphorum.com/news/eu-appr...
January 21, 2026 at 3:27 PM
pharmaphorum.bsky.social
China's #HopstemBiotech has been cleared to start #clinicaltrials of a #stemcell-based therapy for #ischaemicstroke in the US, following negotiations with the FDA.

pharmaphorum.com/news/hopstem...
Hopstem maps course to bring stem cell stroke therapy to US
China's Hopstem has been cleared to move straight to a phase 2 trial in the US for its stem cell-based therapy to aid recovery after a stroke.
pharmaphorum.com
January 21, 2026 at 1:46 PM
pharmaphorum.bsky.social
Shares in #ImmunityBio rose sharply after the company said it has agreed a path with the #FDA that will allow it to refile for approval of wider use of its #bladdercancer therapy, #Anktiva, in papillary-only disease.

pharmaphorum.com/news/immunit...
January 21, 2026 at 12:45 PM
pharmaphorum.bsky.social
Researchers behind a large-scale feasibility trial of a #fingerprick #bloodtest for #type1diabetes (T1D) have said it can identify #children with the disease earlier and allow prompt treatment.

pharmaphorum.com/news/call-go...
Call goes out for type 1 diabetes screening in UK
A finger-prick screening programme for type 1 diabetes should roll out in the UK, say researchers, given a disease-modifying drug is now available.
pharmaphorum.com
January 21, 2026 at 11:04 AM
pharmaphorum.bsky.social
Long-term follow-up data from a phase 2b trial of #Moderna and #MSD's #mRNA-based #vaccine against #melanoma, intismeran autogene (mRNA-4157), show an impressive 49% reduction in the risk of disease progression or death.

pharmaphorum.com/news/data-bu...
January 21, 2026 at 10:39 AM
pharmaphorum.bsky.social
#IsomorphicLabs has added Johnson & Johnson to the roster of pharma companies tapping into its AI-based drug discovery engine.

pharmaphorum.com/news/jj-bets...
J&J bets on Isomorphic for AI-powered drug hunt
Isomorphic Labs has added Johnson & Johnson to the roster of pharma companies tapping into its AI-based drug discovery engine
pharmaphorum.com
January 20, 2026 at 3:11 PM
pharmaphorum.bsky.social
#Pfizer will relinquish its stake in #ViiV in a deal valued at $2.1bn that ramps up Shionogi's interest and simplifies the #HIV specialist's shareholder structure.

pharmaphorum.com/news/viiv-ow...
ViiV ownership shifts as Pfizer sells its stake
Pfizer will relinquish its stake in HIV firm ViiV in a deal valued at $2.1bn that ramps up Shionogi's interest and simplifies its share structure
pharmaphorum.com
January 20, 2026 at 1:55 PM
pharmaphorum.bsky.social
Glimmers of a resurgence in #biotech #IPO activity in 2026 have continued with the news that two more companies – Belgium's #AgomAbTherapeutics and #SpyGlassPharma of the US – are sizing up #investorinterest.

pharmaphorum.com/news/agomab-...
Agomab and Spyglass push the IPO button
Glimmers of a renewal of biotech IPO activity in 2026 have continued with the news that AgomAb and SpyGlass Pharma are sizing up investor interest.
pharmaphorum.com
January 20, 2026 at 12:53 PM
pharmaphorum.bsky.social
#AstraZeneca's push into #CART therapies for #cancer has continued with an agreement to take full control of C-CAR031, an #antiGPC3 therapy for #solidtumours, from #AbelZeta.

pharmaphorum.com/news/astraze...
AstraZeneca pays $630m to get full control of AbelZeta CAR-T
AstraZeneca's push into CAR-T therapies for cancer has continued with an agreement to take full control of C-CAR031 from Chinese partner AbelZeta.
pharmaphorum.com
January 20, 2026 at 11:57 AM
pharmaphorum.bsky.social
#GSK has made its first major #acquisition under new chief executive #LukeMiels, buying US #biotech #RAPT Therapeutics to gain control of a promising therapy for #foodallergies.

pharmaphorum.com/news/gsk-rea...
GSK reaches $2.2bn deal to buy food allergy biotech RAPT
GSK has made its first major acquisition under new CEO Luke Miels, buying RAPT Therapeutics and its food allergy prevention drug ozureprubart.
pharmaphorum.com
January 20, 2026 at 10:35 AM
pharmaphorum.bsky.social
#SunPharma has downplayed a #rumour that it is in talks to acquire #womenshealth specialist #Organon, after a report suggested a $10 billion offer was being discussed.
Sun Pharma says talk of $10bn Organon bid is 'speculative'
India's Sun Pharma has downplayed a rumour that it is in talks to acquire women's health specialist and MSD spinout Organon for $10bn.
buff.ly
January 19, 2026 at 4:30 PM
pharmaphorum.bsky.social
The #EMA has started its review of #DaiichiSankyo and #AstraZeneca's #Enhertu as a first-line therapy for #HER2positive #breastcancer, setting up a possible approval later this year.
EU starts review of first-line Enhertu for breast cancer
EMA starts its review of first-line Enhertu in HER2+ breast cancer, which could dramatically increase the eligible patient population for the drug.
buff.ly
January 19, 2026 at 3:00 PM
pharmaphorum.bsky.social
An #internationaltrial has started to see if a simple #fingerprick #bloodtest could predict the risk of #Alzheimer's disease, before people start showing signs of #cognitivedecline.

pharmaphorum.com/news/could-a...
Could Alzheimer's be predicted with a finger-prick test?
An international trial has started to see if a simple finger-prick blood test could predict Alzheimer's before symptoms start.
pharmaphorum.com
January 19, 2026 at 1:25 PM
pharmaphorum.bsky.social
#Men in #England with high-risk #prostatecancer will finally be able to get treatment with a life-extending drug which has been available in Wales and Scotland for almost three years.
NICE relents, ending postcode access to prostate cancer drug
Men in England with high-risk prostate cancer will soon be able to get treatment with a drug available in Scotland and Wales for almost three years.
buff.ly
January 19, 2026 at 12:00 PM
pharmaphorum.bsky.social
The Supreme Court of the US (#SCOTUS) has agreed to hear a #patentdispute between #Amarin and #Hikma that could have implications for the legality of '#skinnylabels,' which can help #generic drugmakers bypass #intellectualproperty protections.

pharmaphorum.com/news/skinny-...
'Skinny' generic Vascepa label case reaches US Supreme Court
SCOTUS has agreed to hear a patent dispute between Amarin and Hikma that could have implications for 'skinny labels' used by generic manufacturers.
pharmaphorum.com
January 19, 2026 at 10:55 AM